Publicaciones (16) Publicaciones de Carlos Luri Rey

2024

  1. Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross-priming

    Immunological Reviews, Vol. 321, Núm. 1, pp. 143-151

2023

  1. CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects

    Science advances, Vol. 9, Núm. 33, pp. eadf6692

  2. CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary

    Cancer discovery, Vol. 13, Núm. 3, pp. 552-569

  3. Dendritic cells, headhunters for anti-tumor CD8+ T cells in triple-negative breast cancer

    Med

  4. Druggable Targets in Cytokine Release Syndromes

    Clinical Cancer Research, Vol. 29, Núm. 21, pp. 4320-4322

  5. Facts and Hopes on Neutralization of Protumor Inflammatory Mediators in Cancer Immunotherapy

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 23, pp. 4711-4727

  6. Interleukin-18 in cancer immunology and immunotherapy

    Expert Opinion on Therapeutic Targets, Vol. 27, Núm. 11, pp. 1035-1042

  7. Intratumoral Gene Transfer of mRNAs Encoding IL12 in Combination with Decoy-Resistant IL18 Improves Local and Systemic Antitumor Immunity

    Cancer immunology research, Vol. 11, Núm. 2, pp. 184-198

  8. Intratumoral co-injection of NK cells and NKG2A-neutralizing monoclonal antibodies

    EMBO Molecular Medicine, Vol. 15, Núm. 11

  9. Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-β antagonists

    Molecular Therapy - Nucleic Acids, Vol. 33, pp. 668-682

  10. Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic

    OncoImmunology, Vol. 12, Núm. 1

  11. Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma

    Cell Reports Medicine, Vol. 4, Núm. 4

  12. mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy

    Cell Reports Medicine, Vol. 4, Núm. 3

2022

  1. Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy

    Cancer research, Vol. 82, Núm. 23, pp. 4373-4385

  2. Novel strategies exploiting interleukin-12 in cancer immunotherapy

    Pharmacology and Therapeutics, Vol. 239

  3. Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies

    Journal for immunotherapy of cancer, Vol. 10, Núm. 3